

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)



(10) International Publication Number
WO 2022/165122 A1

(51) International Patent Classification:

A61P 25/00 (2006.01) A61P 25/28 (2006.01)
C12N 15/113 (2010.01) A61P 25/14 (2006.01)

(21) International Application Number:

PCT/US2022/014231

(22) International Filing Date:

28 January 2022 (28.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/143,686 29 January 2021 (29.01.2021) US

(71) Applicant: **IONIS PHARMACEUTICALS, INC.**
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **FITZSIMMONS, Bethany**; 2855 Gazelle Court, Carlsbad, CA 92010 (US). **FREIER, Susan, M.**; 2855 Gazelle Court, Carlsbad, CA 92010 (US). **KOR-DASIEWICZ, Holly**; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(74) Agent: **SCARR, Rebecca, B.** et al.; McNeill Baur PLLC, 125 Cambridge Park Dr, Suite 301, Cambridge, MA 02140 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN

(57) Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of HTT RNA in a cell or subject, and in certain instances reducing the amount of HTT protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom or hallmark of a repeat expansion disease. Such repeat expansion diseases include myotonic dystrophy, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, polyglutamine disorders, Fragile X syndrome, and spinocerebellar ataxia. Such symptoms or hallmarks include brain atrophy, muscle atrophy, nerve degeneration, uncontrolled movement, seizure, tremor, anxiety, and depression.



WO 2022/165122 A1